Pfizer (PFE) Free Cash Flow Growth (1y) (2010 - 2026)
Powered by 
Analysis
Pfizer (PFE) Free Cash Flow Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 157.32% |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | -36.24% |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 77.03% |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | -11.32% |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 125.17% |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | -13.16% |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 107.90% |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 96.00% |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | 1,829.52% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 125.17% |
| Mar 29, 2026 | 23.04% |
| Sep 28, 2025 | -0.74% |
| Jun 29, 2025 | 50.37% |
| Mar 30, 2025 | 358.81% |
| Jun 30, 2024 | -13.95% |
| Mar 31, 2024 | 428.77% |
| Jul 2, 2023 | -128.58% |
| Apr 2, 2023 | -98.76% |
| Jul 3, 2022 | -30.96% |
| Apr 3, 2022 | 47.75% |
| Oct 3, 2021 | 243.30% |
| Jul 4, 2021 | 247.13% |
| Apr 4, 2021 | 48.73% |
| Sep 27, 2020 | 86.69% |
| Jun 28, 2020 | 45.31% |
| Mar 29, 2020 | 116.80% |
| Dec 31, 2019 | -21.50% |
| Sep 29, 2019 | -16.28% |
| Jun 30, 2019 | -37.72% |